Enhancing the Quality and Consistency of Your AAV Vector Manufacturing
The push towards more targeted AAV vectors that allow dose reduction is not only about the biology of making the vector more efficient, but also about the manufacturing. The ability to identify, measure, and leverage the viral vector product’s critical quality attributes is central to the success of AAV-based gene therapies.
In this article, we discuss specific areas where innovation in analytical tools and techniques are providing valuable new insights into the quality and consistency of AAV vector manufacturing. We have collated advice from AAV developer industry leaders and the team at Cell & Gene Therapy Insights to provide you with a view into the role of analytical technologies to support the development of AAV-based gene therapies.
Read this article to learn how analytical technologies can address:
- Vector characterization and purity
- Viral genome titer
- Development of a functional AAV potency assay
Download the Article
Share a little information with us to access the entire article now.
Content you'll also find interesting
Recommended Features
-
Image
Tips for Meeting Regulatory Guidelines for AAV Development
Find tips on meeting regulatory guidance for gene therapies from industry experts in cell and gene therapy.
-
Image
Advancing Gene Therapy Delivery
Discover different delivery systems used for advancing gene therapy, including viral and non-viral vectors, and the benefits and challenges of each approach.
-
Image
Understanding Potency in Cell and Gene Therapy Development
Read about the current state of the CGT industry and challenges associated with potency assays and measuring product potency throughout the manufacturing process.
